Turin

• Long-term safety of apraglutide in short bowel syndrome Ended recruitment
  2023-510389-28-00 5 2021-06-14 short bowel syndrome
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa … Ended recruitment
  2024-516868-28-00 4 2021-05-04 Ph+ Acute Lymphoblastic Leukemia
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (M … Ended recruitment
  2023-507188-21-00 5 2021-04-20 Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
• A Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy Ended recruitment
  2023-506525-11-00 5 2021-04-19 Primary Membranous Nephropathy (pMN)
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer
• A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-re … Ended recruitment
  2023-508530-34-00 4 2021-04-19 PIK3CA-Related Overgrowth Spectrum (PROS)
• A study comparing current available therapies with imetelstat for the treatment of intermediate-2 or high-risk MF who are not responding to … Ended recruitment
  2023-509120-17-00 5 2021-04-12 Myelofibrosis
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cel … Ended recruitment
  2024-511637-35-00 5 2021-03-23 Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
• A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemo … Ended recruitment
  2023-506526-37-00 5 2021-03-17 Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended recruitment
  2023-507418-28-00 4 2021-03-15 Solid tumors
• A study to evaluate the benefit and safety of Luspatercept (ACE-536) in adults with myeloproliferative neoplasm-associated myelofibrosis on … Ended recruitment
  2023-507890-17-00 5 2021-02-22 Anemia associated with myeloproliferative neoplasm (MPN)-associated my
• Iberdomide as maintenance therapy after autologous stem cell transplantation in newly diagnosed multiple myeloma patients Ended recruitment
  2024-512354-21-00 4 2021-02-22 Newly diagnosed multiple myeloma
• A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab … Ended recruitment
  2022-500439-35-00 5 2021-02-11 treatment-naive chronic lymphocytic leukemia
• A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended recruitment
  2023-508290-81-00 5 2020-12-18 Immunoglobulin G4-related disease (IgG4-RD)
• Study of the Safety and Efficacy of KRT-232 Combined with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post–Polycythemia Vera M … Ended recruitment
  2024-514468-26-00 9 2020-12-04 Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (Post–PV-MF), O
• Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can … Ended recruitment
  2024-513296-41-00 4 2020-12-03 Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended recruitment
  2023-509358-72-00 5 2020-11-23 Diffuse large B-cell lymphoma
• Safety and Efficacy Study of Epcoritamab in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome Ended recruitment
  2023-504828-25-00 9 2020-11-16 Chronic Lymphocytic Leukemia
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc … Ended recruitment
  2023-506515-18-00 5 2020-10-23 Primary Progressive Multiple Sclerosis (PPMS)
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal … Ended recruitment
  2024-513422-38-00 5 2020-09-28 Newly diagnosed multiple myeloma
• Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Ended recruitment
  2024-512961-15-00 5 2020-08-05 Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation

Showing 457–480 of 632 trials